Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

Data ReadoutpositiveVK2735Positive

AI Analysis

Summary

Viking Therapeutics announced positive topline results from a maintenance study of VK2735, demonstrating 22% placebo-adjusted weight loss at week 33 and validating the viability of multiple dosing regimens (weekly, every other week, and monthly) for sustaining weight loss benefits.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

22% placebo-adjusted weight loss at week 33 with weekly 17.5 mg dosing; no plateau observed; monthly and every other week dosing regimens demonstrated viability for maintaining weight loss

Importance:7/10

Sentiment:

0.80

GLP-1/GIP agonistweight lossmaintenance studydosing regimenPhase 2

Related Companies

$VKTX

Read the original article

Published by PR Newswire Biotech on September 22, 2026 11:05 AM

Read Original